1.4469

1.04% -0.0069

Scienture Holdings Inc (SCNX)

Panoramica Notizia Cronologia dei prezzi Forum Previsione

Precedente Chiudi:

$1.44

Aprire:

$1.43

Volume 24 ore:

68,291

Relative Volume:

0.03

Capitalizzazione di mercato:

$12.95M

Reddito:

Utile/perdita netta:

Rapporto P/E:

EPS:

Flusso di cassa netto:

1 W Prestazione:

-19.49%

1M Prestazione:

-46.23%

6M Prestazione:

-80.45%

1 anno Prestazione:

+0.00%

Intervallo 1D:

$1.3718

$1.48

Intervallo di 1 settimana:

$1.17

$1.88

Portata 52W:

$1.00

$9.55

Scienture Holdings Inc Stock (SCNX) Company Profile

Nome

Scienture Holdings Inc

Settore

Healthcare (1165)

Industria

Pharmaceutical Retailers (9)

Telefono

(800) 261 0281

Indirizzo

2420 BRUNELLO TRACE, LUTZ

Dipendente

Cinguettio

Prossima data di guadagno

Ultimi documenti SEC

SCNX's Discussions on Twitter

Confronta SCNX con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
SCNX Scienture Holdings Inc	1.4469	12.95M	0	0	0	0.00
WBA Walgreens Boots Alliance Inc	11.15	9.66B	147.66B	-8.64B	-363.00M	-10.01
WGRX Wellgistics Health Inc	4.31	224.40M	0	0	0	0.00
HITI High Tide Inc	1.985	152.97M	376.07M	-22.41M	18.73M	-0.298
PETS Petmed Express Inc	4.08	86.55M	270.52M	-6.08M	17.42M	-0.2944

Scienture Holdings Inc Borsa (SCNX) Ultime notizie

Mar 26, 2025

Investors: What’s The Real Deal With Scienture Holdings Inc (NASDAQ: SCNX) - Stocks Register

Mar 26, 2025

Mar 25, 2025

SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization - The Manila Times

Mar 25, 2025

Scienture Gears Up for Major Product Launch: New CCO and Syneos Health Partnership Signal Growth - Stock Titan

Mar 25, 2025

Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days - The Manila Times

Mar 19, 2025

Organovo Announces Reverse Stock Split - The Manila Times

Mar 19, 2025

FDA Approves Revolutionary Liquid Losartan: Scienture's Game-Changing Hypertension Treatment - StockTitan

Mar 19, 2025

Mar 18, 2025

Scienture announces U.S. FDA approval of NDA for SCN-102 - TipRanks

Mar 18, 2025

12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga

Mar 18, 2025

FDA Approves Losartan Potassium for Reduction in Risk of Stroke - Drug Topics

Mar 18, 2025

What's Going On With Scienture Shares Tuesday? - Benzinga

Mar 18, 2025

FDA Approves SCN-102, Liquid Oral Suspension Formulation of Losartan - Pharmacy Times

Mar 18, 2025

Pre-Market Momentum: Scienture (SCNX) Stock Soars After FDA Green Light - Stocks Telegraph

Mar 18, 2025

Scienture Says US FDA Approves Oral Liquid Formulation of Hypertension Drug Losartan - Marketscreener.com

Mar 18, 2025

SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024. - The Manila Times

Mar 18, 2025

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga

Mar 18, 2025

Breakthrough FDA Approval: First-Ever Liquid Hypertension Drug Targets $1.5B Market - StockTitan

Mar 18, 2025

Billionaires Ray Dalio and Paul Tudor Jones Are Piling Into a Hard Asset That Has Trounced Nvidia This Year - The Globe and Mail

Mar 18, 2025

Q4 Earnings Outperformers: D.R. Horton (NYSE:DHI) And The Rest Of The Home Builders Stocks - The Globe and Mail

Mar 18, 2025

Mar 17, 2025

12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga

Mar 17, 2025

4 Quantum Computing Stocks on Watch Today as GTC 2025 Kicks Off - The Globe and Mail

Mar 17, 2025

Mar 15, 2025